Search

everythinglearnresearchcommunity

for

Search:↓

A 25-year-old man had a 3500 graft hair transplant on the frontal region and is happy with the results after 8 months. He has been on minoxidil and finasteride, switched to dutasteride, added ketoconazole shampoo for seborrheic dermatitis, and is considering a second transplant for the mid scalp/crown.

A user diagnosed with AGA is seeking advice on hair loss treatments, comparing topical Minoxidil, Spironolactone, and Finasteride to oral medications and natural methods like dermastamping, PRP, and LED light. They are concerned about side effects and effectiveness, especially given their existing fatigue.

An 18-year-old male with hair loss is considering starting finasteride but is concerned about potential side effects like gynecomastia due to his prolactin levels. He seeks guidance on whether his bloodwork indicates it's safe to begin treatment.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

A 28-year-old male is experiencing excessive hair shedding despite using oral and topical minoxidil, and occasionally using ketoconazole shampoo. He is considering trying GHK-Cu serums but cannot use finasteride.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The user is concerned about hair regrowth after using 2% minoxidil and keraglow vitamins for three months, noticing shedding but no significant improvement. They plan to switch to 5% minoxidil and consider finasteride for better results, as they have been diagnosed with male pattern baldness.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

A user is developing a tool to track hair density, aiming to help those using treatments like minoxidil. They seek feedback on the tool's usefulness and are considering a low-cost model to cover expenses.

High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

The conversation discusses using minoxidil and dutasteride for hair growth, with OP considering amino acids or growth hormone for better results. Another user inquires about the effectiveness of dutasteride.

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

The conversation discusses concerns about potential side effects, specifically gynecomastia, from taking 1mg of finasteride every other day for hair loss. Bloodwork results were shared, but more information was requested to provide advice.

The conversation discusses the anticipation and skepticism around the release of GT20029 for hair loss treatment. The original poster has been using Finasteride and Minoxidil but is hopeful for GT20029, while others express doubts about its timely release and suggest alternatives like KX826 and hair transplants.

A user reported that taking iron polymaltose significantly reduced their hair loss. They also mentioned hair loss due to DHT and asked if hair loss from iron deficiency is permanent or temporary.

The user is concerned about hair loss despite using oral finasteride, oral minoxidil, and topical minoxidil. They are seeking advice on additional blood tests to identify potential causes.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.

The user got blood work to check hormone levels before starting Finasteride for hair loss and is seeking advice on interpreting the results. They are considering hormone levels in relation to potential side effects of Finasteride.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.

The conversation discusses using 2-deoxy-d-ribose (2DDR) for hair regrowth, with users sharing mixed experiences and side effects like hair loss in new areas and increased anxiety. The original poster plans to continue testing and comparing it to minoxidil, noting potential instability in 2DDR formulations.

Betacarotene's effect on hair loss is discussed, with concerns about excessive vitamin A. The user also questions if 15mg melatonin impacts vitamin A levels.

A 35-year-old had a hair transplant with 3,153 grafts at HLC Ankara, experiencing some pain and numbness but pleased with the density and results. The procedure cost $10,000, and the user has been using finasteride for over 13 years.

A 33-year-old man experienced diffuse thinning and hair shedding due to sleep deprivation and low testosterone. After starting hCG treatment, he noticed hair regrowth on his temples.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.

The user is experiencing hair thickening with oral minoxidil but notices worsening hairline and considers starting finasteride despite concerns about gynecomastia. They are also considering using Latisse on their hairline and seek advice on potential outcomes and experiences with these treatments.